Loizzi Vera, Ranieri Girolamo, Laforgia Mariarita, Gadaleta Cosmo Damiano, Gargano Giulio, Kardhashi Anila, De Liso Maria, Naglieri Emanuele, Del Vecchio Vittoria, Cicinelli Ettore, Cormio Gennaro
Department of Biomedical Sciences and Human Oncology, University of Bari, I-70121 Bari, Italy.
Interventional and Medical Oncology Unit, IRCCS Istituto di Ricovero e Cura a Carattere Scientifico 'Giovanni Paolo II', I-70124 Bari, Italy.
Oncol Lett. 2020 Oct;20(4):90. doi: 10.3892/ol.2020.11951. Epub 2020 Aug 6.
Epithelial ovarian cancer (EOC) has a poor prognosis. Since the introduction of paclitaxel as antineoplastic agent >20 years ago, only a few phase III randomized trials have shown challenging data regarding different therapeutic options for facing its aggressive clinical course and granting active therapies to patients. Different studies have shown the utility of poly(ADP-ribose) polymerase (PARP) inhibitors in women with EOC with or without mutations, both germline and somatic. Three PARP inhibitors, olaparib, rucaparib and niraparib, have been recently approved by the Food and Drug Administration for clinical use in EOC patients, though with different clinical indications and profiles of toxicity, while two other molecules, veliparib and talazoparib, are still under clinical investigation. The aim of the present paper is to evaluate the current status of PARP inhibitors in terms of molecular activity, pharmacodynamic properties and clinical applications.
上皮性卵巢癌（EOC）预后较差。自20多年前紫杉醇作为抗肿瘤药物引入以来，只有少数III期随机试验显示了关于应对其侵袭性临床病程并为患者提供积极治疗的不同治疗选择的具有挑战性的数据。不同研究表明，聚（ADP - 核糖）聚合酶（PARP）抑制剂对有或没有种系和体细胞突变的EOC女性有用。三种PARP抑制剂，奥拉帕利、鲁卡帕利和尼拉帕利，最近已被美国食品药品监督管理局批准用于EOC患者的临床治疗，尽管它们有不同的临床适应症和毒性特征，而另外两种分子，维利帕利和他拉唑帕利仍在临床研究中。本文的目的是从分子活性、药效学特性和临床应用方面评估PARP抑制剂的现状。
